Efficacy of tolterodine as a first‐line treatment for non‐neurogenic voiding dysfunction in children

Abstract

Tolterodine combined with behavioural modification for dysfunctional voiding in children with no neurological or anatomical abnormality can be recommended as a first-line treatment before invasive evaluation. Additionally, the DVSS appears to provide accurate and objective data for monitoring the effect of treatment in such children.